RxDoctor Payments Data

Brandy Burt

Psychiatric/Mental Health · Goshen, INNPI 1902575145

Payments from drug & device makers

$1,338in general payments, 2019–2025

Across 79 payments — averaging $16.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$315
  • Alkermes, Inc.$232
  • Teva Pharmaceuticals USA, Inc.$196
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$148
  • Neurocrine Biosciences, Inc.$146
  • Axsome Therapeutics, Inc.$88
  • plus $213 from 5 others

What the payments were for

  • Food & beverage$1,18689%
  • Education$15211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,338 in reported general payments places this provider in the 65th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$5,674
Medicare patients
14
Services billed
70

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate29$83,555
VivitrolNaltrexone Microspheres12$21,297
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl59$7,718
Aripiprazole28$2,714
Oxcarbazepine13$1,059
Bupropion XlBupropion Hcl58$830
Carbamazepine13$812
Naltrexone Hcl20$783
Fluoxetine Hcl41$738
Buspirone Hcl69$730
Topiramate19$712
Methylphenidate Hcl32$612
Venlafaxine Hcl ErVenlafaxine Hcl24$528
Buprenorphine Hcl13$527
Quetiapine Fumarate51$527

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Alkermes, Inc.Vivitrol$232$21,29712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Goshen

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →